The company’s CEO has been appointed to a new government role by President-elect Donald Trump, but there are more factors at ...

and HOUSTON, Nov. 13, 2024 /PRNewswire/ -- Continuity Biosciences, LLC, a new bioscience company dedicated ... PhD (Co-Founder & CEO), a former senior executive at AbbVie with expertise in drug ...

and HOUSTON, Nov. 13, 2024 /PRNewswire/ -- Continuity Biosciences, LLC, a new bioscience company dedicated ... PhD (Co-Founder & CEO), a former senior executive at AbbVie with expertise in drug ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

While A.I. promises breakthroughs, industry leaders warn that transparency and patient safety must remain front and center.

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

Gain insight on Rigel Pharmaceuticals, AbbVie and more in the latest Market Talks covering the Health Care sector.

Most U.S. stocks are rising Monday and adding to the gains made during their best week of the year. The S&P 500 was up 0.2% ...

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent ...